NCT02804945View on ClinicalTrials.gov

Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 24, 2017

Primary Completion Date

June 13, 2019

Study Completion Date

June 13, 2019

Conditions
Blood And Marrow TransplantationAdult Respiratory Distress Syndrome
Interventions
BIOLOGICAL

Mesenchymal Stem Cells (MSCs)

Participants receive a maximum dose of 3 x 10\^6 cell/Kg by vein one time on Day 1.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Katz Foundation

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER

NCT02804945 - Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies | Biotech Hunter | Biotech Hunter